News

AOL3mon
FDA Approves Sanofi's Hemophilia Drug - AOL
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce ...
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Applied Clinical Trials Online4d
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
The American Journal of Managed Care1mon
FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A
Previously, Jivi was approved in September 2018 for adults and adolescents aged 12 years and older with this hemophilia subtype. 2 According to data collected from federally funded hemophilia ...
Benzinga.com3mon
FDA Approves Sanofi's Hemophilia Drug - Benzinga
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.